Comparative Pharmacology
Head-to-head clinical analysis: DISOPHROL versus MUCINEX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOPHROL versus MUCINEX D.
DISOPHROL vs MUCINEX D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
Mucinex D contains guaifenesin, which is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity and enhance mucus clearance, and pseudoephedrine, a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
Mucinex D contains guaifenesin 600 mg and pseudoephedrine 60 mg per extended-release tablet. Usual adult dose: 1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
Guaifenesin: 1 hour (short t½, requires frequent dosing). Pseudoephedrine: 5-8 hours (prolonged with alkaline urine)
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Guaifenesin: Renal (primarily as metabolites, <5% unchanged). Pseudoephedrine: Renal (70-90% unchanged, dependent on urine pH)
Category C
Category C
Antihistamine/Decongestant Combination
Expectorant/Decongestant Combination